ARISTO

Aristo Bio-Tech and Lifescience Share Price

₹151.45 +7.2 (4.99%)

21 Nov, 2024 14:19

SIP TrendupStart SIP in ARISTO

Start SIP

Performance

  • Low
  • ₹151
  • High
  • ₹151
  • 52 Week Low
  • ₹53
  • 52 Week High
  • ₹164
  • Open Price₹151
  • Previous Close₹144
  • Volume8,000

Investment Returns

  • Over 1 Month + 24.91%
  • Over 3 Month + 53.06%
  • Over 6 Month + 89.91%
  • Over 1 Year + 116.36%
SIP Lightning

Smart Investing Starts Here Start SIP with Aristo Bio-Tech and Lifescience for Steady Growth!

Invest Now

Aristo Bio-Tech and Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 103
  • P/B Ratio
  • 3.1
  • Average True Range
  • 8.77
  • EPS
  • 5.72
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.63
  • RSI
  • 56.48
  • MFI
  • 64.89

Aristo Bio-Tech and Lifescience Financials

Aristo Bio-Tech and Lifescience Technicals

EMA & SMA

Current Price
₹151.45
+ 7.2 (4.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹139.38
  • 50 Day
  • ₹127.33
  • 100 Day
  • ₹114.52
  • 200 Day
  • ₹100.58

Resistance and Support

144.25 Pivot Speed
  • R3 144.25
  • R2 144.25
  • R1 144.25
  • S1 144.25
  • S2 144.25
  • S3 144.25

What's your outlook on Aristo Bio-Tech and Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Aristo Bio-Tech And Lifescience has an operating revenue of Rs. 796.21 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 2% needs improvement, ROE of 11% is good. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 52% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 24% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 88 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 45 indicates it belongs to a fair industry group of Chemicals-Agricultural and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aristo Bio-Tech and Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results & Others To consider other business matters.
2024-05-27 Audited Results & Dividend
2023-11-07 Quarterly Results
2023-05-27 Audited Results & Dividend
Date Purpose Remarks
2023-09-15 FINAL Recommended Final Dividend of 0.25 per equity share

Aristo Bio-Tech and Lifescience F&O

Aristo Bio-Tech and Lifescience Shareholding Pattern

73.37%
23.69%
2.94%

About Aristo Bio-Tech and Lifescience

  • NSE Symbol
  • ARISTO
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Narendra Singh Barhat
  • ISIN
  • INE082101010

Similar Stocks to Aristo Bio-Tech and Lifescience

Aristo Bio-Tech and Lifescience FAQs

Aristo Bio-Tech and Lifescience share price is ₹151 As on 21 November, 2024 | 14:05

The Market Cap of Aristo Bio-Tech and Lifescience is ₹103.1 Cr As on 21 November, 2024 | 14:05

The P/E ratio of Aristo Bio-Tech and Lifescience is As on 21 November, 2024 | 14:05

The PB ratio of Aristo Bio-Tech and Lifescience is 3.1 As on 21 November, 2024 | 14:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23